Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Seamless Clinical Study Evaluating the Efficacy, Safety, PK, PD, and ADA of MG-K10 Humanized Monoclonal Antibody Injection in the Treatment of Seasonal Allergic Rhinitis
Conditions
Interventions
Placebo
MG-K10 Humanized Monoclonal Antibody Injection
Locations
1
China
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Start Date
March 20, 2025
Primary Completion Date
May 31, 2025
Completion Date
September 30, 2025
Last Updated
April 18, 2025
NCT04815668
NCT06837233
NCT06046391
NCT03570957
NCT05540717
NCT02320396
Lead Sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions